Portal de Periódicos da CAPES

Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation

2016; Elsevier BV; Volume: 128; Issue: 11 Linguagem: Inglês

10.1182/blood-2016-06-723205

1528-0020

Raffaella Greco, Francesca Lorentino, Mara Morelli, Fabio Giglio, Daniele Mannina, Andrea Assanelli, Sara Mastaglio, Serena Dalto, Tommaso Perini, Lorenzo Lazzari, Simona Piemontese, Consuelo Corti, Magda Marcatti, Massimo Bernardi, Maria Teresa Lupo Stanghellini, Fabio Ciceri, Jacopo Peccatori,

Immune Cell Function and Interaction

To the editor: Graft-versus-host disease (GVHD), both acute and chronic, is still a leading cause of nonrelapse mortality after transplantation.[1][1] High-dose, posttransplantation cyclophosphamide (PTCy) is an attractive approach for in vivo allodepletion across the HLA barrier in allogeneic